STAGE III BREAST CANCER

This early-phase trial tests a DNA vaccine called STEMVAC in 42 people with advanced HER2-negative breast cancer. The vaccine aims to train the immune system to attack cancer stem cells, which are resistant to standard treatments. The study focuses on safety and whether the vacci…

This study looks at whether aerobic exercise can lower ctDNA levels in the blood, which may help prevent cancer from returning. About 33 people who have been treated for high-risk breast, prostate, or colorectal cancer will try different amounts of weekly exercise to find the saf…

This study tests whether giving two targeted drugs (T-DM1 and pertuzumab) before surgery can completely eliminate cancer in women with early-stage HER2-positive breast cancer. About 164 participants with stage II or III disease will receive the combination, then have surgery to c…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) is better than capecitabine at preventing breast cancer from coming back in people with a specific type of triple-negative breast cancer (basal-like) that was not completely removed by initial chemoth…

This study tests whether combining an immunotherapy drug (avelumab) with other medications can help shrink or control advanced triple-negative breast cancer that has spread or cannot be removed by surgery. About 145 adults with stage IV or recurrent triple-negative breast cancer …

This study tested whether giving chemotherapy (paclitaxel and cyclophosphamide) with or without the targeted drug trastuzumab before surgery helps shrink breast cancer tumors in 92 women with early-stage or locally advanced breast cancer. The goal was to see if the treatment redu…

This study tests whether a newer drug, Margetuximab, works better than the standard drug Trastuzumab when combined with chemotherapy and another targeted therapy before surgery for stage II-III HER2-positive breast cancer. About 174 participants will receive one of the two drug c…